You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
NYAB Q3´24: Strong order backlog
NYAB released its Q3 report today, marking its second as a listed company in Sweden. In this interview, CEO Johan Larsson summarizes the quarter, discusses the Uppsala project, the demand situation and the record high order backlog.
Read the report here: Well positioned for future growth
Herantis Pharma as an Investment | Life Science Night Dec. 2, 2024
Aiforia as an Investment | Life Science Night Dec. 2, 2024
Faron Pharmaceuticals as an Investment | Life Science Night Dec. 2, 2024
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Life Science Night | December 2, 2024
Titta på alla videor